ArticleBMC pregnancy and childbirth2026
Association between G6PD gene variants and adverse pregnancy outcomes.
Article in BMC pregnancy and childbirth, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveGlucose-6-phosphate dehydrogenase (G6PD) deficiency is primarily characterized by neonatal jaundice and acute/chronic hemolytic anemia. This study aimed to examine the influence of different G6PD genotypes on pregnancy and neonatal outcomes.
methodsBetween 2020 and 2021, a total of 225 male neonates identified as carriers of G6PD variants through neonatal screening and 121 male healthy controls were included. Blood samples from neonates with initially positive G6PD enzyme activity and their mothers were analyzed for common G6PD variants using the melting-curve assay. Statistical analyses were performed to assess enzyme activity, genetic variants, and maternal–fetal clinical phenotypes.
resultsTen variant sites were identified, with c.1376G > T (47.11%), c.1388G > A (26.67%), c.95 A > G (6.22%) and 1024 C > T (6.22%) exhibiting the highest frequencies. Significant statistical differences were observed between variant carriers and controls in G6PD enzyme activity, gestational age at birth, preterm birth rate, and incidence of jaundice (p < 0.01). Among neonates, enzyme activity was significantly correlated with the incidence of jaundice (p < 0.01). G6PD gene variant was identified as a risk factor for preterm birth (OR = 13.01, p = 0.013). Pregnant women with comorbid cholestasis (OR = 10.114, p = 0.014) or cytopenia (OR = 3.186, p = 0.046) demonstrated an increased risk of preterm birth. Furthermore, pregnant women carrying G6PD gene variants comorbid with gestational diabetes mellitus had an increased risk of abortion (OR = 2.634, p = 0.02).
conclusionAdverse pregnancy outcomes are the result of the combined effects of multiple factors, and G6PD gene variants when mixed with maternal diseases, may increase the risk of preterm birth and abortion. In regions with elevated carrier prevalence, preconception and prenatal testing of G6PD enzyme activity, alongside carrier screening, may enhance maternal and neonatal health management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.